LG to develop a new modified osteoarthritis drug.
Published: 2005-09-02 06:57:00
Updated: 2005-09-02 06:57:00
LG Life Science has succeeded in developing Hyruan plus, a degenerative osteoarthritis drug having 6 months to one year sustained relieving effects only by 3 times administration, at about 4 billion won of investment for the R&D over 6 years.
The company announced on Aug. 30 that the drug wil...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
